Dual subtyping may be particularly important for tumours which are ER+ or ERlow by clinical typing and molecularly basal‐like, as these malignancies have been characterised to respond very differently to therapeutic agents than other clinically ER+ tumours.91 The gene discussed is ESR1; the disease is neoplasm.